Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.910
-0.020 (-2.15%)
At close: Nov 20, 2024, 4:00 PM
0.950
+0.040 (4.38%)
After-hours: Nov 20, 2024, 7:58 PM EST
Palatin Technologies Employees
Palatin Technologies had 30 employees as of June 30, 2024. The number of employees decreased by 4 or -11.76% compared to the previous year.
Employees
30
Change (1Y)
-4
Growth (1Y)
-11.76%
Revenue / Employee
$79,470
Profits / Employee
-$1,078,459
Market Cap
17.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Concord Medical Services Holdings | 727 |
Marinus Pharmaceuticals | 166 |
Retractable Technologies | 151 |
ProPhase Labs | 113 |
American Shared Hospital Services | 31 |
MEI Pharma | 28 |
Cognition Therapeutics | 28 |
Akari Therapeutics, | 12 |
PTN News
- 6 days ago - Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 7 days ago - Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - PRNewsWire
- 12 days ago - Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - PRNewsWire
- 17 days ago - Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PRNewsWire
- 21 days ago - Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - PRNewsWire
- 4 weeks ago - Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium - PRNewsWire
- 4 weeks ago - Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium - PRNewsWire
- 6 weeks ago - Palatin Receives Notice of Non-Compliance from NYSE American - PRNewsWire